BACKGROUND: @entity3562 occurs in @entity177 and may increase the risk for @entity65 , possibly by damaging the endothelium. @entity1501 and @entity7727 are required in two separate @entity1255 conversion pathways and may therefore lower plasma @entity1255 . OBJECTIVE: To study the therapeutic role of @entity7727 and the effect on endothelial function of long-term @entity1255 -lowering therapy with @entity1501 , in @entity298 ( @entity298 ) @entity1 . @entity1 AND DESIGN: Thirty @entity298 @entity1 were randomized to a 12-week treatment with 5 mg @entity1501 and 4 g @entity7727 daily, or to 5 mg @entity1501 alone daily. They were then rerandomized to treatment with 1 or 5 mg @entity1501 daily for 40 weeks. MEASUREMENTS: At baseline and after 52 weeks, endothelial function was assessed by determination of endothelium-dependent vasodilatation and biochemical markers. RESULTS: Plasma total @entity1255 (tHcy) was elevated at baseline: 42.6 (5.8) micromol/L. Only 1 @entity1 (3%) had a normal plasma @entity1255 (i.e., < or = 15 micromol/L) before therapy. Normalization of plasma @entity1255 occurred in 39% of the @entity1 at 12 weeks. @entity7727 had no additional @entity1255 -lowering effect. Plasma tHcy levels were similar during treatment with 1 or 5 mg @entity1501 daily. Endothelial function was impaired at baseline and had not improved after 52 weeks of treatment. CONCLUSIONS: Peritoneal dialysis @entity1 have @entity3562 , which can be normalized with @entity1501 alone in about 40% of @entity1 . @entity7727 does not further lower plasma @entity1255 . A maintenance dose of 1 or 5 mg @entity1501 daily results in equivalent plasma @entity1255 levels. Long-term reduction in plasma @entity1255 did not result in improvement of endothelial function as assessed by our methods.

@entity1501 treatment of XXXX in @entity298 @entity1 : no change in endothelial function after long-term therapy.

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid', 'Folic acid'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity7727 :: ('MESH:D001622', 'Chemical') :: ['Betaine', 'betaine'] @entity3562 :: ('MESH:D020138', 'Disease') :: ['Hyperhomocysteinemia', 'hyperhomocysteinemia'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity3562 :: (MESH:D020138,Disease) :: ['hyperhomocysteinemia']
